VeraLight Gets $17.5M

Albuquerque, New Mexico-based VeraLight, a medical device company developing a non-invasive diabetes screening device, has raised $17.5M. The firm said that the Series B round was led by Psilos Group, and included new investor CMEA Ventures. Previous investors vSpring Capital, Wasatch Venture Fund, The Dow Chemical Company, and the Southern Ute Growth Fund all participated. Lisa Suennen of Psilos and David Collier of CMEA have joined the firm's board in conjunction with the funding. VeraLIght said that the funding will be used to complete development, testing, and introduction of its diabetes screening system. More information »